SureTrader
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
 
Followed By 26
Posts 3,555
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Avid Bioservices to Participate in Cambridge Healthtech Institute’s (CHI) 8th Annual The Bioprocessing Summit "GlobeNewswire Inc." - 8/9/2016 8:05:00 AM
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments "GlobeNewswire Inc." - 7/14/2016 4:05:00 PM
Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center "GlobeNewswire Inc." - 7/14/2016 8:05:00 AM
Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 201... "GlobeNewswire Inc." - 7/7/2016 4:05:00 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 6/2/2016 4:00:00 PM
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Deve... "GlobeNewswire Inc." - 6/2/2016 8:05:00 AM
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic... "GlobeNewswire Inc." - 4/20/2016 8:05:00 AM
Form 8-K - Current report "Edgar (US Regulatory)" - 4/12/2016 4:31:41 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 3/9/2016 7:46:45 PM
Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility "GlobeNewswire Inc." - 3/9/2016 7:46:43 PM
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016 "GlobeNewswire Inc." - 3/9/2016 7:46:38 PM
Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab "GlobeNewswire Inc." - 3/9/2016 7:46:14 PM
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments "GlobeNewswire Inc." - 3/9/2016 8:00:00 AM
Peregrine Alert -- National Securities Law Firm Continues Investigation of Peregrine Pharmaceuticals, Inc. for Potential Secu... "PR Newswire (US)" - 2/29/2016 9:30:00 AM
Peregrine Alert -- National Securities Law Firm Investigates Peregrine Pharmaceuticals, Inc. for Potential Securities Law Cla... "PR Newswire (US)" - 2/26/2016 3:09:00 PM
Four Biotech Small Caps with Near Term Catalysts to Keep on Your Radar "InvestorsHub NewsWire" - 1/27/2016 8:00:00 AM
Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences "GlobeNewswire Inc." - 1/20/2016 8:05:00 AM
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Canc... "GlobeNewswire Inc." - 1/11/2016 8:05:00 AM
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Canc... "GlobeNewswire Inc." - 1/6/2016 8:05:00 AM
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments "GlobeNewswire Inc." - 12/10/2015 4:05:00 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 12/7/2015 4:05:00 PM
It's the Little Things That Matter for Peregrine Pharmaceuticals "The Motley Fool" - 12/4/2015 10:46:03 AM
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015 "GlobeNewswire Inc." - 12/3/2015 4:05:00 PM
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences "GlobeNewswire Inc." - 11/23/2015 8:05:00 AM
Feature Analyst Alert and 4 Brief Updates "InvestorsHub NewsWire" - 11/10/2015 8:00:00 AM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 271156 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.

Paul

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist